ReviewClinical research in cardiology : official journal of the German Cardiac Society2021
Timely and individualized heart failure management: need for implementation into the new guidelines.
Review in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial).ESC heart failure · 2023Trial
- EVOLUTION-HF DEESC heart failure · 2025Article
- Device therapy for patients with atrial fibrillation and heart failure with preserved ejection fraction.Heart failure reviews · 2024Review
- Multifocal ectopic premature Purkinje-related complexes syndrome in children.HeartRhythm case reports · 2023Article
- Structural components for the development of a heart failure network.ESC heart failure · 2023Review
- A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction.ESC heart failure · 2023Review
- Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis.American heart journal plus : cardiology research and practice · 2023Article
- Application of recommended therapies among patients with heart failure during the Syrian conflict: reality and barriers.ESC heart failure · 2022Article
- Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials.ESC heart failure · 2022Review
- Association of Repetitive Dosing of Levosimendan with Reduction of NYHA Class and NT-proBNP Levels in Decompensated Heart Failure: A Retrospective Cohort Study.Drugs - real world outcomes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to remarkable improvements in heart failure (HF) management over the last 30 years, a significant reduction in mortality and hospitalization rates in HF patients with reduced ejection fraction (HFrEF) has been observed. Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve outcomes for patients with HFrEF to reduce mortality and HF hospitalization. This includes established device therapies, such as implantable defibrillators and cardiac resynchronization therapies, which improved patients' symptoms and prognosis. Over the last 10 years, new HF drugs have merged targeting various pathways, such as those that simultaneously suppress the renin-angiotensin-aldosterone system and the breakdown of endogenous natriuretic peptides (e.g., sacubitril/valsartan), and those that inhibit the I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.